Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel

被引:21
作者
Samra, Z
Yardeni, M
Peled, N
Bishara, J
机构
[1] Rabin Med Ctr, Infect Dis Unit, IL-49100 Petah Tiqwa, Israel
[2] Rabin Med Ctr, Dept Clin Microbiol, IL-49100 Petah Tiqwa, Israel
[3] Tel Aviv Univ, Sackler Sch Med, IL-49100 Petah Tiqwa, Israel
[4] Rabin Med Ctr, Recanati Ctr Med & Res, IL-49100 Petah Tiqwa, Israel
关键词
D O I
10.1007/s10096-005-0005-y
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To evaluate the species distribution and antifungal susceptibility of Candida isolates in a tertiary institution in Israel, all consecutive isolates of Candida spp. recovered from blood during the last 2 years were studied. The isolates were identified by the germ tube test and the API ID 32C test (bioMerieux, Marcy l'Etoile, France). MICs of antifungal agents were determined by the E test. Candida albicans was the most commonly isolated species, accounting for 44% (63/142) of the isolates, followed by Candida tropicalis (25%; 35/142), Candida parapsilosis (20%; 29/142), Candida glabrata (10%; 14/142), and Candida krusei (0.7%; 1/142). All isolates were sensitive to amphotericin B and voriconazole. Resistance to fluconazole (using a high MIC of >= 256 mu g/ml) was found in 1.6% of C. albicans isolates, in 3.4% of C. parapsilosis isolates, and in 21.4% of C. glabrata isolates. Resistance to itraconazole was detected in 3.2% of C. albicans isolates, in 2.9% of C. tropicalis isolates, in 3.4% of C. parapsilosis isolates, and in 93% of C. glabrata isolates. Disparities in species distribution and antifungal susceptibility of Candida isolates from the institute studied versus Candida isolates from other centers and countries are described. The findings emphasize the need for continuous surveillance and further clinical investigational studies.
引用
收藏
页码:592 / 595
页数:4
相关论文
共 13 条
[1]  
Hung CC, 1996, J FORMOS MED ASSOC, V95, P19
[2]   Risk factors for Candida tropicalis fungemia in patients with cancer [J].
Kontoyiannis, DP ;
Vaziri, I ;
Hanna, HA ;
Boktour, M ;
Thornby, J ;
Hachem, R ;
Bodey, GP ;
Raad, II .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (10) :1676-1681
[3]  
National Committee for Clinical Laboratory Standards, 2002, M27A2 NCCLS
[4]   Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods:: Report from the ARTEMIS global antifungal susceptibility program, 2001 [J].
Pfaller, MA ;
Diekema, DJ ;
Messer, SA ;
Boyken, L ;
Hollis, RJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (04) :1440-1446
[5]   International surveillance of bloodstream infections due to Candida species:: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program [J].
Pfaller, MA ;
Jones, RN ;
Doern, GV ;
Sader, HS ;
Hollis, RJ ;
Messer, SA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (07) :1886-1889
[6]   National epidemiology of mycoses survey:: A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species [J].
Pfaller, MA ;
Messer, SA ;
Houston, A ;
Rangel-Frausto, MS ;
Wiblin, T ;
Blumberg, HM ;
Edwards, JE ;
Jarvis, W ;
Martin, MA ;
Neu, HC ;
Saiman, L ;
Patterson, JE ;
Dibb, JC ;
Roldan, CM ;
Rinaldi, MG ;
Wenzel, RP .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 31 (01) :289-296
[7]   Twelve years of fluconazole in clinical practice:: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida [J].
Pfaller, MA ;
Diekema, DJ .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 :11-23
[8]   International surveillance of bloodstream infections due to Candida species:: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program [J].
Pfaller, MA ;
Diekema, DJ ;
Jones, RN ;
Sader, HS ;
Fluit, AC ;
Hollis, RJ ;
Messer, SA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (09) :3254-3259
[9]   Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro in vivo correlation data for fluconazole, itraconazole, and Candida infections [J].
Rex, JH ;
Pfaller, MA ;
Galgiani, JN ;
Bartlett, MS ;
EspinelIngroff, A ;
Ghannoum, MA ;
Lancaster, M ;
Odds, FC ;
Rinaldi, MG ;
Walsh, TJ ;
Barry, AL .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :235-247
[10]   Changing distribution of Candida species isolated from sterile and nonsterile sites in Israel [J].
Samra, Z ;
Bishara, J ;
Ashkenazi, S ;
Pitlik, S ;
Weinberger, M ;
Lapidoth, M ;
Yardeni, M ;
Levy, I .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (07) :542-545